Form 4 for PCVX Vaxcyte, Inc.
Accepted 2024-09-18 00:00:00 ET · period of report 2024-09-16 · accession 0001649094-24-000068 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-09-18 | 2024-09-16 | PCVX | Wassil Jim | COO | S - Sale+OE | $115.97 | -10.0K | 200.6K | -5% | -$1.16M |
| D | 2024-09-18 | 2024-09-16 | PCVX | Wassil Jim | COO | M - OptEx | $2.42 | +10.0K | 212.0K | +5% | +$24.2K |
| D | 2024-09-18 | 2024-09-16 | PCVX | Wassil Jim | COO | M - OptEx | $0.00 | -10.0K | 42.6K | -19% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-09-16 | S | D | 7,994 | $116.14 | 202,180 | D | — | — | (F3) The price reported is a weighted-average price. The shares were sold at prices ranging from $115.715 to $116.71. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 2 | Common | Common Stock | 2024-09-16 | S | D | 1,784 | $115.06 | 210,174 | D | — | — | (F2) The price reported is a weighted-average price. The shares were sold at prices ranging from $114.50 to $115.45. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 3 | Common | Common Stock | 2024-09-16 | M | A | 10,000 | $2.42 | 211,958 | D | — | — | |
| 4 | Common | Common Stock | 2024-09-16 | S | D | 222 | $116.96 | 200,646 | D | — | — | (F4) The Reporting Person entered into a divorce settlement agreement with his ex-spouse (the "Settlement Agreement") pursuant to a "domestic relations order" as defined in Section 16(a)(12) of the Securities Exchange Act of 1934, as amended. On September 17, 2024, the Reporting Person transferred 1,312 shares of Vaxcyte, Inc. Common Stock to his ex-spouse pursuant to the Settlement Agreement. Accordingly, the Reporting Person will not report beneficial ownership of or dispositions of the disposed shares in future Section 16(a) filings. |
| 5 | Derivative | Stock Option (right to buy) | 2024-09-16 | M | D | 10,000 | $0.00 | 42,638 | D | $2.42 · — to 2029-12-16 | 10,000 Common Stock | (F5) 1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter. |